This “superbug” test can precisely identify multiple types of drug-resistant Staphylococcus bacterial infections in one hour, including Methicillin-resistant Staphylococcus aureus — an antibiotic-resistant form of the Staph bacteria that kills more Americans than HIV every year.
The Staphylococcus Test uses three different proprietary biomarker targets to determine which types of Staph are present and which carry the antibiotic-resistant gene.
The technology, licensed by St. George, Utah-based DxNA, allows for more rapid diagnosis, improved treatment of patients and reduced medical costs.
TGen and NAU expect future patent approvals for the technology from the U.S., Canada, European Union, Japan and Brazil.
More articles on supply chain:
Failed drug study opens door to cheaper drug development: 3 things to know
Some weight loss drugs more effective than others: 6 findings
Novartis clashes with Colombia over high drug costs
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
